Trial Profile
Phase I, 5-period, open-label study evaluating potential drug–drug interactions between ceftolozane/tazobactam and drugs metabolised by CYP1A2 or CYP3A4 or transported by organic anion transporters OAT1 and OAT3 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2015
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary) ; Caffeine; Furosemide; Midazolam
- Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
- Focus Adverse reactions; Pharmacokinetics
- 08 Oct 2015 New trial record